Author: Editor

Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, discusses topics covered by scientists from the Francis Crick Institute at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. These include Tim Hunt, Richard Treisman, Nicholas Luscombe, Erik Sahai and Adrian Hayday. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, gives an overview of the featured sessions of the 2015 National Cancer Research Institute (NCRI) Cancer Conference. These include sessions by Alberto Bardelli, Thierry Voet, Erik Sahai, Adrian Hayday, James Larkin, Sergio Quezada, Robert Peston and Fabrice André. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, gives an overview of the 2015 National Cancer Research Institute (NCRI) Cancer Conference, which will focus on integrating basic, translational and clinical cancer research, and cover topics such as cancer evolution, single cell genomics, cancer immunology, cancer cell cycle and health economics in cancer. Key speakers and hosts include Thierry Voet, Alberto Bardelli, Adrian Hayday, Sergio Quezada, Tim Hunt, Denis Slamon and Robert Peston. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Previously, risk reduction from treatment with endocrine therapy has been represented as a general percentage for all patients treated. Knowing that in reality each patient responds differently, Dr. Naughton stresses the importance of tailoring treatment decisions based on the individual patient situation. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, discusses Trial Assigning IndividuaLized Options for Treatment (TAILORx), a prospective phase 3 clinical trial that was designed to evaluate the utility of the Oncotype DX® Breast Cancer Assay to risk stratify patients with oestrogen receptor-positive, HER2-negative, node-negative breast cancer. By identifying low-risk patients who are unlikely to benefit from adjuvant chemotherapy, the test may allow physicians to direct patients to individualised therapies that are associated with improved health outcomes. This content is supported by Genomic Health, Inc. European Medical Journal…

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses an open-label, biomarker-directed, multi-drug, multi-centre, multi-arm, randomised phase 1b clinical trial in patients with muscle-invasive urothelial carcinoma of the bladder who have progressed on prior treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Naughton discusses the bothersome side effects and serious safety risks associated with endocrine therapy. He emphasizes the need to weigh patient benefit versus the impact on quality of life due to these side effects and safety risks when considering patient treatment options. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, outlines potential therapeutic applications, including immune and adaptive approaches, of an improved understanding of cancer genes and mutational processes. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses Patient Reported Opinions about Clinical Tolerability (PROACT), a mobile platform designed to enable patients to directly contribute to the understanding of investigational agents in early clinical development. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Riccardo A. Audisio, MD, FRCS, of the University of Liverpool, St. Helens Teaching Hospital, St. Helens, UK, discusses a European Registration of Cancer Care (EURECCA) international comparison of treatment patterns for patients aged 70 years and older with non-metastatic breast cancer in four European countries. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

@OncEd Presents Dr. Nancy Zhu – Case-Based Discussion for Managing MDS Patients. This live webinar took place on September 10, 2015.

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, explains that anti-tumour immunity has the potential to be exploited clinically against the evolutionary process that drives cancer development. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Keith M. Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses the results from the European Thoracic Oncology Platform (ETOP) Lungscape Project, a study of the molecular epidemiology of resected stage I-III non-small cell lung cancer (NSCLC) tumours and association with clinicopathological features and outcomes in patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, reviews the emerging understanding of mutational drivers of tumour heterogeneity, including APOBEC-mediated mutagenesis, that could support the development of future therapeutic strategies. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

@OncEd Presents Dr. Martin Reck – ECC 2015 Immunotherapy Updates

@OncEd Presents Dr Luis Bruno – ECC 2015 GU Cancer Highlights (Portuguese Version)

@OncEd Presents Dr. Stephanie Snow – ECC 2015 Head and Neck Updates

@OncEd Presents Dr. Scott Berry – ICECREAM Trial

@OncED Presents Dr. Scott Berry – COMET Trial

@OncEd Presents Dr. Nadia Harbeck – PALOMA 3 Trial

@OncEd Presents Dr. Ralph Wong – Neuroendocrine Tumour Updates

@OncEd Presents Dr. Ramon Andrade de Mello – Hypermethylation of the TERT Promoter (Portuguese Version)

@OncEd Presents Dr. Ramon Andrade de Mello – Hypermethylation of the TERT Promoter

@OncEd Presents Dr. Silke Gillessen – SAKK 08/11 Study

@OncEd Presents Dr. Vladimir Milovanov – Predicting incomplete cytoreduction and aborted HIPEC in PC

@OncEd Presents Dr. Juan Pablo Marquez Manriquez – Multi-Antigen Vaccination for Colon Cancer Treatment and Prevention

@OncEd Presents Dr. Sunil Verma – ECC 2015 Breast Cancer Updates

@OncEd Presents Dr. Jeff Weber – Novel Combinations with Checkpoint Inhibitors

@OncEd Presents Dr. Stephen Doral Stefani – Access and Equity

@OncEd Presents Dr. Wolfgang Janni – DETECT Study

@OncEd Presents Dr. Jean Fayette – UNICANCER Trial

@OncEd Presents Dr Michael Untch – GEPARQUINTO Study

@OncEd Presents Dr. Fernando Rivera – PEAK Trial

At the European Cancer Congress (ECC) 2015, Mark Lawler, PhD, of Queens University Belfast, Belfast, UK, Richard Sullivan, MD, PhD, of King’s College London, London, UK, and Francesco de Lorenzo, MD, of European Cancer Patient Coalition (ECPC), Brussels, Belgium, discuss the ECPC initiative, Europe of Disparities in Cancer, which was designed to evaluate the position of European cancer patients on the increasing inequalities in cancer care in Europe. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

In patients with early stage breast cancer, there is a need to identify prognostic factors to determine the risk of recurrence and predictive factors to determine the optimal adjuvant therapy. At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, discusses prognostic and predictive biomarkers that are enabling more individualised therapies to be applied in molecularly defined breast cancer subgroups. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

@OncEd Presents Dr. Christos Sotiriou – NEOALTTO Trial

@OncEd Presents Dr. Linda Lindstrom – ST03 Trial

@OncEd Presents Dr. Neal Shore – TAK-385 Trial

@OncEd Presents Visualization and relaxation as anxiety reducing techniques – Dr. Andreas Charalambous. From ECC 2015 in Vienna, Austria.

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a first-in-human study of the first-in-class fatty acid synthase inhibitor, TVB-2640, as monotherapy or in combination for the treatment of patients with solid malignancies. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Giorgio V. Scagliotti, MD, PhD, of the University of Turin, Turin, Italy, discusses the exploratory analysis of frontline therapies in REVEL, a randomised phase 3 clinical trial of ramucirumab plus docetaxel versus docetaxel for the treatment of patients with stage 4 non-small cell lung cancer after disease progression on platinum-based therapy. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr Naughton discusses challenges facing women who are evaluating extention of adjuvant endocrine treatment and how he finds Breast Cancer Index helpful.

At the European Cancer Congress (ECC) 2015, Peter Naredi, MD, PhD, of the University of Gothenburg, Gothenburg, Sweden, chairs a news briefing with Matteo Lambertini, MD, of IRCCS AOU San Martino-IST, Genova, Italy; Martine Frouws, MD, of Leiden University Medical Centre, Leiden, The Netherlands; and Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif, France. They discuss the results from a clinical trial evaluating post-diagnosis aspirin use; the Combi-v clinical trial; and an analysis of hormonal therapy for preventing ovarian failure and preserving fertility in breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

European Cancer Patient Coalition (ECPC) is the largest European cancer patients’ umbrella organisation, representing 365 patient organisations in 40 European countries. The Europe of Disparities in Cancer initiative, a framework developed by ECPC, was designed to improve the survival and quality of life for cancer patients in Europe. Presented at the European Cancer Conference (ECC) 2015 by Francesco de Lorenzo, MD, of ECPC, Brussels, Belgium European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

There is a growing divide in cancer healthcare and survivorship between populations across Europe. European Cancer Patient Coalition (ECPC), the largest European cancer patients umbrella organisation, presented the paper, Europe of Disparities in Cancer, which discusses the position of European cancer patients on the increasing inequalities in cancer care in Europe, and provides a set of scientifically validated, patient-friendly, patient-oriented recommendations on the most important approaches to address these inequalities. Presented at the European Cancer Conference (ECC) 2015 by Richard Sullivan, MD, PhD, of King’s College London, London, UK European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Neal Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, SC, discusses the first interim analysis of a phase 2, randomised, open-label, parallel group clinical trial of TAK-385, an oral gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of patients with advanced prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

European Cancer Patient Coalition (ECPC), the largest European cancer patients umbrella organisation, presented the paper, Europe of Disparities in Cancer, which discusses the position of European cancer patients on the increasing inequalities in cancer care in Europe. Europe of Disparities in Cancer is a scientifically validated, patient-friendly, patient-oriented set of recommendations on the most important approaches to address the inequalities in cancer care across Europe, including the need for better cancer health literacy, and access to cancer screening and early detection. Presented at the European Cancer Conference (ECC) 2015 by Mark Lawler, PhD, of Queens University Belfast, Belfast, UK European…

A meta-analysis was conducted to include 12 randomised trials and a total of 1,231 breast cancer patients receiving chemotherapy, with or without luteinising hormone-releasing hormone analogue (LHRHa). Initial results showed the rates of premature ovarian failure (POF) were reduced by 64% in patients who received LHRHa. However, the studies used different definitions of POF, and results ranged widely. The analysis was then restricted to trials that included specific data on whether a womans periods had re-started one year after chemotherapy. In the eight relevant trials, the rates of POF were reduced by 45% with LHRHa and there was close agreement…

Genomic interventions may improve disease-risk stratification and patient-tailored treatment. At the European Cancer Congress (ECC) 2015, John Crown, MD, MBA, of St Vincents University Hospital, Dublin, Ireland, outlines the processes and challenges surrounding the health economic evaluation of genomic technologies in Europe. Clinical trials, such as the prospective validation of a 21-gene expression assay in breast cancer (Trial Assigning IndividuaLized Options for Treatment, TAILORx), are providing the data necessary to define the clinical utility of genomic profiling tests. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreview

At the European Cancer Congress (ECC) 2015, John Crown, MD, MBA, of St Vincents University Hospital, Dublin, Ireland, discusses the low-risk registry results from Trial Assigning IndividuaLized Options for Treatment (TAILORx). TAILORx is a prospective phase 3 clinical trial designed to evaluate the role of endocrine therapy and chemoendocrine therapy in patients with oestrogen receptor (ER)-positive, HER2-negative, node-negative breast cancer whose treatment was guided by the Oncotype DX® Breast Cancer Assay Recurrence Score® results. The results showed that adding genomic information provided by the Oncotype DX® Breast Cancer Assay may influence the selection of patients for adjuvant chemotherapy based on…